DAX20.268 +2,4%ESt504.771 +2,5%Top 10 Crypto10,87 -1,1%Dow38.836 +2,3%Nas16.001 +2,6%Bitcoin71.773 -1,1%Euro1,0912 ±-0,0%Öl63,93 -0,7%Gold3.007 +0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Tesla A1CX3T Amazon 906866 Apple 865985 RENK RENK73 Infineon 623100 Allianz 840400 Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 Deutsche Bank 514000 Microsoft 870747 Volkswagen (VW) vz. 766403 BYD A0M4W9
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Fokus auf Zollkonflikt: DAX auf Stabilisierungskurs -- Wall Street mit kräftiger Erholung -- Infineon kauft Automotive-Ethernet-Sparte von Marvell -- Conti, Tesla, Rüstungsaktien, Porsche im Fokus
Top News
Bill Ackman sieht rot: Den USA steht ein "wirtschaftlicher nuklearer Winter" bevor Bill Ackman sieht rot: Den USA steht ein "wirtschaftlicher nuklearer Winter" bevor
Bitcoin, Ether & Co: So schlagen sich die Kryptowährungen am Dienstagnachmittag Bitcoin, Ether & Co: So schlagen sich die Kryptowährungen am Dienstagnachmittag
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Hoth Therapeutics Aktie

NeuKaufenVerkaufen
0,7700 USD +0,0077 USD +1,01 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone

Marktkap.9,48 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DZJ0

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS44148G2049

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolHOTH

Hoth Therapeutics Aktien News

DatumMeistgelesen
PR NewswireHoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ
PR NewswireHoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain inte...
PR NewswireHoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
PR NewswireHoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
PR NewswireHoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours ...
PR NewswireHoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
PR NewswireHoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual M...
PR NewswireHoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
PR NewswireHoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
PR NewswireHoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
PR NewswireHoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
PR NewswireHoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025
PR NewswireHoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
PR NewswireHoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
PR NewswireHoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
PR NewswireHoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
PR NewswireHoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
PR NewswireHoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
PR NewswireHoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
PR NewswireHoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
PR NewswireHoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic
PR NewswireHoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
PR NewswireHoth Therapeutics Expands Clinical Trial for Cancer Patients
PR NewswireHoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery
PR NewswireHoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024
PR NewswireHoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
PR NewswireHoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
PR NewswireHoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
PR NewswireHoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
PR NewswireHoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
PR NewswireHoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
PR NewswireHoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
PR NewswireHoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies
PR NewswireHoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT
PR NewswireHoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023
PR NewswireHoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery
PR NewswireFDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients
PR NewswireHoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia
PR NewswireHoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients
PR NewswireHoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa
Wer­bung

Hoth Therapeutics News

Hoth Therapeutics News: auf dieser Seite finden Sie alle Hoth Therapeutics News und Nachrichten zur Hoth Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Hoth Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Hoth Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.